TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34750081
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg subcutaneously monthly (every 2 weeks if on apheresis)
Study: 34750296
Drug: Romidepsin (RMD)
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin (RMD) as latency-reversing agent
Study: 34750494
Drug: Multi-Arm Sequential
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-Arm Sequential Trial with Efficient Recruitment (MASTER) design
Study: 34750557
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus platinum-pemetrexed chemotherapy
Study: 34750557
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and pemetrexed chemotherapy (historical control)
Study: 34750637
Drug: Dostarlimab 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab 1, 3, or 10 mg/kg intravenously every 2 weeks (part 1)
Study: 34750637
Drug: Dostarlimab 500
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab 500 mg every 3 weeks (Q3W)
Study: 34750637
Drug: Dostarlimab 1000
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab 1000 mg every 6 weeks (Q6W)
Study: 34750637
Drug: Dostarlimab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab (all doses)
Study: 34751002
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic therapy (AST) discussion referrals
Study: 34751002
Drug: Adjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immunotherapy trials
Study: 34751259
Drug: ChAdOx1 MERS
Normalized name: mersalyl
DrugBank: Mersalyl (DB09338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 MERS vaccine (single intramuscular injection)
Study: 34752491
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) and Deep Learning (DL) approaches applied to fetuses and newborns with CDH for predicting neonatal pulmonary hypertension (PH)
Study: 34752491
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) and Deep Learning (DL) approaches
Study: 34753703
Drug: Cetuximab added
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab added to first-line chemotherapy (CT) in SCC patients with positive EGFR FISH and IHC (N=58)
Study: 34753762
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of an unspecified intervention (not detailed in the abstract)
Study: 34753777
Drug: Mogamulizumab 1
Normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mogamulizumab 1 mg/kg plus Nivolumab 240 mg
Study: 34753871
Drug: Digital pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital pill system (DPS)
Study: 34753870
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) interruption after achieving >99.5% host cell replacement in peripheral blood by day 147.
Study: 34753894
Drug: mRNA-1273 COVID-19
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 COVID-19 vaccine (Moderna) - 2 doses
Study: 34754193
Drug: Sevelamer Hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer Hydrochloride (SH) 2,400 mg
Study: 34754193
Drug: Lanthanum Carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum Carbonate (LC) 1,000 mg
Study: 34754429
Drug: ADPKD-specific pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADPKD-specific pain assessment tool (APAT) administered longitudinally in a randomized high-water intake trial.
Study: 34754429
Drug: Pain severity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain severity and associated analgesic use in ADPKD participants.
Study: 34755131
Drug: Neoadjuvant nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant nivolumab treatment
Study: 34755137
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) administered biweekly for 3 to 4 doses before surgery
Study: 34756674
Drug: HDL particle
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL particle concentration < 3.5 μmol/L and total cholesterol ≤ 96 mg/dL in AH patients
Study: 34757194
Drug: UV-oHSV2-stimulated NK92
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV-oHSV2-stimulated NK92 cells with anti-NKG2A and anti-HLA-E treatment
Study: 34757489
Drug: PIPAC-OX (oxaliplatin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPAC-OX (oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy)
Study: 34757602
Drug: Pirfenidone tablets
Normalized name: Pirfenidone Tablets
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone tablets
Study: 34757602
Drug: Pirfenidone capsules
Normalized name: Pirfenidone Capsules
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone capsules
Study: 34757602
Drug: Pirfenidone (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (tablets and substitution)
Study: 34757829
Drug: Advanced obesity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced obesity treatment
Study: 34757973
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) adherence measured electronically in a subcohort of 324 clients.
Study: 34758995
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 0.6 µg/kg in 10 min followed by continuous infusion at 0.4 µg/kg/hour until dural closure)
Study: 34761160
Drug: 24-hour estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour estimated excretion from spot urine sample
Study: 34762093
Drug: ATRA and
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA and arsenic trioxide regimen (chemotherapy-free) for standard-risk APL
Study: 34762093
Drug: ATRA and
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA and arsenic trioxide regimen with 4 doses of idarubicin during induction therapy for high-risk APL
Study: 34763665
Drug: D-chiro-inositol (DCI)
Normalized name: chiro-inositol, (+)-
DrugBank: D-chiro-Inositol (DB15350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-chiro-inositol (DCI) 600 mg, two times per day for 30 days
Study: 34763776
Drug: 0.10 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 or 0.15 mL of MB
Study: 34765307
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg every 2 weeks until disease progression or unacceptable toxicity
Study: 34765593
Drug: Kinect-Based Constraint-Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinect-Based Constraint-Induced Therapy Program
Study: 34766217
Drug: Polatuzumab vedotin-based
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin-based chemotherapy (including regimens other than BR)
Study: 34766217
Drug: Polatuzumab vedotin-based
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin-based chemotherapy
Study: 34766217
Drug: Polatuzumab vedotin-based
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin-based chemotherapy with subsequent hematopoietic stem cell transplantation (HSCT)
Study: 34766576
Drug: Negative IgG
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative IgG anti-HAV antibody status
Study: 34766576
Drug: Negative IgG
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative IgG HBV surface antibody status
Study: 34766576
Drug: Association with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association with use of anti-tumor necrosis factor agents
Study: 34767652
Drug: Filgrastim at
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim at 5 μg/kg in morbidly obese patients
Study: 34767652
Drug: Filgrastim at
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim at 5 μg/kg in non-obese patients
Study: 34767652
Drug: Filgrastim dosing
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim dosing based on actual body weight
Study: 34767759
Drug: mRNA-1273 COVID-19
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 COVID-19 vaccine (100 μg in 0.5 mL intramuscularly, 2 doses, 28 days apart)
Study: 34767765
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (HPV4) or nonavalent HPV vaccine (HPV9) administered in three doses over 6 months (on day 1, at month 2, and at month 6).
Study: 34768176
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose protocol with prolonged infusion
Study: 34768692
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (BFT) performed once or twice a week during the temporary stoma period
Study: 34772746
Drug: Meditation programme
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meditation programme (12 weekly sessions of 1.5 hours each)
Study: 34772758
Drug: Tremelimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (10 mg/kg) + MEDI3617 (200 mg)
Study: 34772758
Drug: Tremelimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (10 mg/kg) + MEDI3617 (600 mg)
Study: 34773596
Drug: fNIRS-guided rTMS
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fNIRS-guided rTMS treatment (n=20)
Study: 34773596
Drug: MEP-guided rTMS
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEP-guided rTMS treatment (n=16)
Study: 34775134
Drug: Intravenous colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous colistin methanesulfonate (CMS) at 2.5-5.0 mg/kg/day
Study: 34775220
Drug: MK-1654 (neutralizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1654 (neutralizing monoclonal antibody)
Study: 34775220
Drug: MK-1654 (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1654 (≥ 75 mg)
Study: 34778571
Drug: adjunctive dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: adjunctive dexamethasone
Study: 34778701
Drug: New medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New medical therapy
Study: 34778998
Drug: Sutimlimab, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutimlimab, an investigational C1s inhibitor
Study: 34779146
Drug: short-term preoperative
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: short-term preoperative endocrine therapy (pET) with tamoxifen or aromatase inhibitors
Study: 34779146
Drug: aromatase inhibitor-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: aromatase inhibitor-based pET
Study: 34780283
Drug: Loop Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loop Insulin Dosing System
Study: 38101902
Drug: Milvexian 25
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian 25 mg twice daily
Study: 38101902
Drug: Milvexian 50
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian 50 mg twice daily
Study: 39214801
Drug: Milvexian 100
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian 100 mg twice daily
Study: 38101902
Drug: Milvexian 200
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian 200 mg twice daily
Study: 38101902
Drug: Milvexian 25
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian 25 mg once daily
Study: 34780683
Drug: Milvexian 50
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian 50 mg once daily
Study: 34780683
Drug: Milvexian 200
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian 200 mg once daily
Study: 34780709
Drug: Ceritinib 510
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 510 mg/m²
Study: 34780709
Drug: Ceritinib 500
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 500 mg/m²
Study: 34781168
Drug: LY2780301 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2780301 500 mg QD + paclitaxel 80 mg/m²
Study: 34781168
Drug: LY2780301 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2780301 + weekly paclitaxel
Study: 34781256
Drug: Sulfadoxine-pyrimethamine plus
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine plus amodiaquine (5 monthly rounds)
Study: 34784953
Drug: Pharmacotherapy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy for AUD or referral for AUD services
Study: 34785698
Drug: WT2725 dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: WT2725 dosing emulsion
Study: 34786087
Drug: OCT-guided drug
Normalized name: Urimar Reformulated Oct 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCT-guided drug coated balloon (DCB)
Study: 34786477
Drug: Nilotinib, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib, 300 mg
Study: 34786477
Drug: Nilotinib, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib, 150 mg
Study: 34786649
Drug: L-Ornithine phenylacetate
Normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Ornithine phenylacetate
Study: 34786667
Drug: Peptide p5+14
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide p5+14 radiolabeled with iodine-124, single intravenous infusion
Study: 34787590
Drug: Automated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated treatment (AT)
Study: 34788228
Drug: Cosyntropin infusion
Normalized name: Cosyntropin
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cosyntropin infusion (ACTH(1-24))
Study: 34788228
Drug: Cosyntropin infusion
Normalized name: Cosyntropin
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cosyntropin infusion
Study: 34788401
Drug: Venetoclax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH)
Study: 34788506
Drug: Autologous hematopoietic
Normalized name: Autologous Hematopoietic Peripheral Blood Stem Cells
DrugBank: Autologous Hematopoietic Peripheral Blood Stem Cells (DB17067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with an α-L-iduronidase (IDUA)-encoding lentiviral vector after myeloablative conditioning
Study: 34789156
Drug: Plasma soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma soluble urokinase plasminogen activator receptor (suPAR) levels ≥ 14.7 ng/mL
Study: 34789304
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of highly malignant or malignant EEG pattern with background frequency of delta waves or undetermined
Study: 34789490
Drug: Serology for
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serology for SARS-CoV-2 IgG antibodies introduced in 2020
Study: 34789494
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly singing sessions facilitated by Breathe Arts Health Research
Study: 34789774
Drug: Deep learning
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep learning (DL) network for predicting early on-treatment response in mCRC.
Study: 34789774
Drug: Size-based methodology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Size-based methodology for predicting early on-treatment response in mCRC.
Study: 34790261
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy
Study: 34790348
Drug: Seralutinib (inhaled),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seralutinib (inhaled), administered for 24 weeks
Study: 34790348
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered for 24 weeks
Study: 34790371
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg once daily) plus S-1 (40-60 mg twice daily on days 1-14)
Study: 34791634
Drug: Conventional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional triamcinolone acetonide crystalline suspension (TAcs) 40 mg
Study: 34791755
Drug: Novel low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Novel low-dose paclitaxel-coated balloon with citrate-based excipient (Agent PCB)
Study: 34792107
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (CAPOX)
Study: 34792477
Drug: Teleassessments using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teleassessments using a computer tablet and testing equipment shipped to participants' homes
Study: 34792559
Drug: Nicotinamide (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (1000 to 3000 mg) and pyruvate (1500 to 3000 mg)
Study: 34793256
Drug: Venetoclax (dose-escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (dose-escalated from 200 mg to a maximum of 800 mg daily for up to 2 years)
Study: 34793505
Drug: WRSs2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSs2 vaccine
Study: 34793505
Drug: WRSs3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSs3 vaccine
Study: 34793505
Drug: WRSs2 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSs2 and WRSs3 vaccines
Study: 34793719
Drug: Single-agent evorpacept
Normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent evorpacept (0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg once per week; 30 mg/kg once every other week)
Study: 34793719
Drug: Evorpacept plus
Normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evorpacept plus pembrolizumab (200 mg every 3 weeks)
Study: 34793719
Drug: Evorpacept plus
Normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evorpacept plus trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks)
Study: 34793719
Drug: Evorpacept (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evorpacept (30 mg/kg once every other week)
Study: 34793719
Drug: Evorpacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evorpacept (10 mg/kg once per week)
Study: 34793923
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plaque features (matrix, intraplaque hemorrhage [IPH], wall thickness, plaque burden) and clinical features (age, body mass index, lipid levels)
Study: 34794396
Drug: neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy with liposomal irinotecan (nal-IRI), oxaliplatin (OX), and 5-fluouracil/folinic acid (FA) (NAPOX)
Study: 34794420
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) starting dosage 30 mg/kg/day in 6 hours
Study: 34794989
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy with androgen deprivation therapy (ADT) and intensification with agents such as docetaxel, abiraterone acetate, and enzalutamide.
Study: 34794989
Drug: Local cytoreductive
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local cytoreductive approaches (external beam radiotherapy, cytoreductive radical prostatectomy, or minimally invasive ablative therapy) and metastases-directed therapies (metastasectomy or stereotactic ablative body radiotherapy).
Study: 34795408
Drug: Pamiparib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib (60 mg BID, RP2D; 80 mg BID, MTD)
Study: 34795408
Drug: Pamiparib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib (80 mg BID)
Study: 34795408
Drug: Pamiparib (dose-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib (dose-escalation phase)
Study: 34795661
Drug: High TTV
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High TTV viraemia (>10,000 copies/ml)
Study: 34795912
Drug: Combination pemetrexed-cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination pemetrexed-cisplatin chemoradiotherapy